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ABSTRACT
With the recent approval of tocilizumab as 
the first biologic for the treatment of systemic 
juvenile idiopathic arthritis (sJIA), an important 
unmet medical need for this historically 
challenging disease has now been met. The 
purpose of this review article is to revisit the 
established therapeutic options for sJIA, to 
summarize the history of the clinical trials 
with tocilizumab, and to discuss its role in the 
treatment of sJIA.
Keywords: anti-interleukin-6; systemic juvenile 
idiopathic arthritis; tocilizumab
INTRODUCTION
Systemic juvenile idiopathic arthritis (sJIA) 
affects between 5% and 15% of all children with 
JIA in North America and Europe [1]. In Asia, 
however (including India and Japan), this form 
of the disease may account for up to 50% of 
all JIA cases [2,3]. Despite being relatively rare, 
sJIA is responsible for nearly two thirds of all 
childhood arthritis mortality [4-6]. Although 
sJIA is equally distributed among girls and boys 
and can occur at any age, it often affects younger 
children [7,8]. 
The diagnosis of sJIA is a diagnosis of 
exclusion requiring a thorough work-up of 
infectious diseases and malignancies, especially 
in those patients in whom arthritis is absent at 
onset. Diagnostic criteria include a history of 
arthritis in any number of joints and at least 
2 weeks of daily monophasic or biphasic fevers 
accompanied by at least one of the following:
•	 evanescent, salmon-pink-colored rash on 
the trunk or overlying the joints; 
•	 hepatosplenomegaly;
•	 generalized lymphadenopathy;
•	 serositis (pericarditis, pleuritis).
It is well known that arthritis may be absent 
at disease onset, which often leads to delays 
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in early diagnosis. Characteristic lab findings 
include leukocytosis, anemia of chronic 
inflammation, thrombocytosis, elevated acute-
phase reactants, and signs of disseminated 
intravascular coagulation [9]. 
Macrophage activation syndrome (MAS), 
especially during the active systemic phase 
of the disease, represents the most serious 
complication and is associated with a high 
mortality rate [10,11]. 
Prior to the introduction of the newer 
biologic treatments approximately one third 
of sJIA patients had a monophasic disease 
course and more than half developed erosive 
polyarticular arthritis, with potential long-term 
disability [2,9,12].
Although the etiology of sJIA remains 
unknown, recent scientific evidence seems 
to suggest that this subform of JIA has many 
traits of an autoinflammatory rather than 
an autoimmune disorder, and leukocyte 
transcriptional signatures can be used to 
distinguish sJIA from other febrile illnesses 
[13]. Pascual et al. analyzed transcriptional 
patterns of freshly isolated blood mononuclear 
cells from patients with active sJIA in addition 
to analyzing transcriptional changes induced 
upon culturing healthy blood mononuclear 
cells with serum from active sJIA patients [14]. 
The results revealed that sJIA serum upregulated 
interleukin-1 (IL-1) transcription in healthy cells 
and that IL-1 protein secretion was induced in 
a disease-activity-dependent manner. IL-1β-
induced genes such as pentraxin 3, potassium 
inward-rectifier channel, subfamily J, member 
15 (KCNJ15), or adenosine triphosphate (ATP)-
sensitive inward rectifier potassium channel 
were found to be upregulated in peripheral 
blood mononuclear cells in the majority of 
active sJIA patients. These patterns normalized 
after treatment with anakinra. Additionally, 
mononuclear cells from patients with active sJIA 
were found to secrete excess IL-1β protein upon 
activation, while interleukin-6 (IL-6) and tumor 
necrosis factor (TNF) production did not differ 
significantly from controls, suggesting a specific 
dysregulation of the IL-1 pathway in patients 
with sJIA [14].
As reviewed previously, IL-1 is the key 
cytokine in autoinflammatory syndromes and 
an important mediator of sJIA [15,16]. IL-1β 
and IL-1α are formed from pro-IL-1 via caspase 
activity. While IL-1α is mostly membrane-bound, 
IL-β is synthesized by monocytes, macrophages, 
and dendritic cells and plays a pivotal role 
in the induction of fever and rash and 
stimulates the level of circulating IL-6 [12-15]. 
In addition, other cytokines such as IL-6, 
interleukin-7 (IL-7), and interleukin-18 (IL-18) 
play a more dominant role in this disease than 
in other forms of JIA. Increased plasma levels 
of IL-6 and IL-1 result in higher levels of acute-
phase reactants and myeloid-related proteins 
(MRP 8 and 14), increased production and 
mobilization of platelet and white blood cells, 
and anemia [15-23].
Conversely, IL-6 is a pleiotropic cytokine that 
regulates immune responses and inflammatory 
reactions. IL-6, alone or with other cytokines, 
interacts with various cells such as T cells, 
B cells, lymphocytes, monocytes, and fibroblasts, 
driving synovial proliferation, inflammation, 
autoimmunity, and destruction of articular 
structures through the activation of osteoclasts 
[24]. Both membrane-bound interleukin-6 
receptor (IL-6R) and the soluble form of IL-6R are 
able to mediate proinflammatory IL-6 signaling 
through the interaction with the cytokine 
receptor subunit glycoprotein gp130 [25]. 
Like IL-1, IL-6 is associated with many of the 
manifestations of sJIA such as fever, rash, 
lymphadenopathy, hepatosplenomegaly, 
anemia, and poor growth [21,22]. Markedly 
increased IL-6 levels in serum and synovial fluid 
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are one of the hallmark features of sJIA. IL-6 is 
especially elevated during or just before fever 
spikes, while it is often only marginally elevated 
in between fever attacks [18]. 
An extensive literature search was conducted using 
the PubMed and Ovid medical databases. Keywords 
included search terms such as “juvenile idiopathic 
arthritis,” “systemic,” “arthritis,” “macrophage 
activation syndrome,” “treatment,” “anakinra,” 
“IL-1ra,” “rilonacept,” and “tocilizumab,” and 
searches for interleukins 1, 6, 15, and 18. 
Traditionally treatment for sJIA has been 
challenging, partly as a result of long-term 
corticosteroid toxicity and limited efficacy of 
traditional disease-modifying antirheumatic 
drugs (DMARDs) such as methotrexate and 
cyclosporine [26,27]. On the other hand, due to 
the autoinflammatory nature of sJIA, anti-TNF 
agents have shown very limited efficacy in sJIA 
in comparison to other forms of JIA [28-30].
Subsequent to the recognition that 
IL-1 dysregulation may contribute to the 
pathogenesis of sJIA [31], multiple studies 
have demonstrated the dramatic clinical 
impact of IL-1 blockade in the form of either 
an IL-1 receptor antagonist (IL-ra, anakinra), a 
monoclonal anti-IL-1 antibody (canakinumab), 
or rilonacept (an IL-1 type I receptor and IL-1 
receptor accessory protein fusion protein also 
known as IL-1 Trap), with rapid induction of 
clinical remission in patients with sJIA [32-39]. 
A recently published study [32] retrospectively 
examined anakinra as first-line therapy (either in 
monotherapy [10/46 patients] or in combination 
with steroids and or DMARDs [36/46 patients] in 
46 children with active sJIA (all with active fevers 
and rash) with a median age of 7.5 years who 
were started on treatment an average of 80 days 
after disease onset. Treatment was associated 
with rapid resolution of systemic symptoms 
and, more remarkably, prevention of arthritis in 
almost 90% of patients during the observation 
period. The authors concluded that treatment 
with anakinra was most favorable when initiated 
early in the disease, before arthritis had become 
well established. In most cases, treatment with 
anakinra avoided protracted corticosteroid 
use and prevented the development of severe, 
therapy-resistant arthritis. 
A similar observation was made by 
Gattorno et al. in their study of 22 patients 
with active systemic-onset JIA (fever in 
17/22 and rash in 12/22) [33]. They found 
that complete responders to anakinra had a 
smaller number of joints with active disease 
at baseline and a higher absolute neutrophil 
count compared with patients who were 
incomplete responders or nonresponders. 
In another study, by Pascual et al., anakinra 
treatment in 9 children with active sJIA (7/9 with 
fevers and rashes) resulted in a complete treatment 
response in 7/9 [31]. The patients with the best 
response to anakinra had less articular involvement 
and a higher total white blood cell count, similar to 
those observed in the Gattorno study.
Lastly, in the study by Quartier et al. in which 
24 children with sJIA were treated with anakinra 
(mean age 8.5 years, mean disease duration 
3.7 years, and mean active joint count 16), 
the initial beneficial treatment effect in most 
patients was lost over time, illustrating that 
a treatment response to IL-1 inhibition is less 
favorable in those patients with more advanced 
sJIA, since only about a third of patients in this 
study had active fevers at baseline [34]. 
The rilonacept trial enrolled 24 patients, all 
with fevers and or rash. The median age was 
14 years, the mean disease duration was 3 years, 
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and the average joint count was 10. Patients 
received rilonacept 2.2 mg/kg or 4.4 mg/kg 
or placebo subcutaneously, with a maximum 
allowable weekly dose of 320 mg (4.0 mL). 
A history of anakinra use was recorded in 
29% of the patients. At 3 months from study 
initiation, the adapted American College of 
Rheumatology (ACR) pediatric 30, 50, and 70 
responder rates were 78.3%, 60.9%, and 34.8%, 
respectively, which improved further during the 
open-label period. In patients previously treated 
with anakinra (n=7), the adapted ACR pediatric 
70 responder rate at the 12-month evaluation was 
85.7% (6/7). The clinically significant reduction 
in systemic disease manifestations that was 
observed during the double-blind phase was 
maintained during open-label treatment, which 
exemplifies again the beneficial role of anti-IL-1 
treatment in the early stages of sJIA [38,39]. 
Finally, similar observations were made in the 
various treatment studies with canakinumab. 
In the initial phase 2 dose escalation study of 
canakinumab in 25 patients with advanced 
sJIA (median disease duration of 38 months 
and a mean of 20 [range, 4-62] swollen joints 
at baseline), patients received canakinumab in 
doses ranging from 0.5 to 9 mg/kg. Seventeen 
of them had been previously treated with 
anakinra. Fifty-nine percent of the children 
reached an ACR pediatric 50 response within 
15 days, and 4 patients achieved inactive disease. 
Six of the eleven nonresponders to anakinra 
responded to a single dose of canakinumab. 
Notably, nonresponders had a substantially 
higher number of active joints (median, 
33.5 joints) and somewhat lower levels of 
systemic inflammation relative to responders 
(median, 9 joints) [36]. 
Comparable results were seen in the 
subsequent two phase 3 studies with 
canakinumab in 84 patients with sJIA [40]. In this 
study the average age of patients was 8.5 years 
and the average disease duration was fairly 
short at 2 years. All patients had fevers and/or 
rash, but the inclusion criteria required those 
symptoms to be present only for at least a day. 
Even though the average swollen joint count 
was about 8, the range was fairly high, with 
some patients having up to 58 swollen joints. 
After a month of treatment, ACR pediatric 
50 and 100 were achieved by 76% and 32% of 
the patients compared to only 5% and 2.4% of 
the patients on placebo. In general, monthly 
dosing with canakinumab (4 mg/kg/month) 
significantly reduced the risk of flare and enabled 
successful steroid tapering/discontinuation 
while demonstrating an acceptable safety and 
tolerability profile. Infections, predominantly 
of the upper respiratory tract, some serious, 
were the most frequent adverse events reported. 
A total of 5 cases of MAS were observed including 
4 patients  in the canakinumab and one patient 
in the  placebo groups, three of which were 
considered life-threatening, and two of which 
resulted in death [40].
Safety of Anti-IL-1 Treatments
To my knowledge, none of the published 
anti-IL-1 trials reported treatment-related deaths, 
malignancies, or opportunistic infections, 
including tuberculosis. In general infections 
occur more frequently with anti-IL-1 agents 
than in placebo-treated patients, and serious 
infections have been reported but appear to be 
generally rare.
Treatment with Tocilizumab
Tocilizumab (Actemra®; Hoffmann-La Roche 
Ltd., Ontario, Canada) is a humanized, 
monoclonal anti-IL-6 receptor antibody that 
binds to soluble and membrane-bound IL-6 
receptors, specifically blocking IL-6 actions [24].
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History
Two phase 2 clinical trials and one phase 3 trial 
demonstrating the clinical efficacy and safety 
of tocilizumab in systemic-onset JIA have been 
published [41-43]. 
Like the clinical trials with anti-IL-1 agents, 
most trials employed the modified ACR pediatric 
definition of improvement for assessment in 
sJIA, which addresses the improvement of the 
systemic inflammatory features of the disease 
[44]. Fever and characteristic rash are key clinical 
features of sJIA, and the modified ACR pediatric 
criteria require meeting the ACR definition of 
improvement and improvement or resolution 
of sJIA-associated fever and rash [45]. 
The first clinical trial examining the 
evidence for tocilizumab in the treatment 
of sJIA was published by Yokota et al. after 
initial compassionate use of tocilizumab in 
four children with sJIA [41]. In this double-
blind intention-to-treat trial with open-label 
run-in, successive randomization, and open-
label extension, 56 Japanese children (aged 
2-19 years) with treatment-refractory sJIA were 
given three doses of tocilizumab 8 mg/kg every 2 
weeks during a 6-week open-label lead-in phase. 
At the end of the open-label lead-in phase, 
ACR pediatric 30, 50, and 70 responses were 
achieved by 51 (91%), 48 (86%), and 38 (68%) 
of the patients, respectively. Forty-three patients 
continued to the double-blind phase, where 
4/23 patients (17%) in the placebo group 
maintained an ACR pediatric 30 response and 
a C-reactive protein (CRP) concentration of less 
than 15 mg/L compared with 16 of 20 (80%) in 
the tocilizumab group (P<0.0001). By week 48 
of the open-label extension phase, 47 (98%), 
45 (94%), and 43 (90%) of 48 patients, 
respectively, achieved ACR pediatric 30, 50, and 
70 responses [43]. The most common adverse 
events included mild infections and transient 
increases in transaminases. Serious adverse events 
included anaphylactoid reactions, gastrointestinal 
hemorrhage, bronchitis, and gastroenteritis.
This trial was followed by an open-label phase 
2 trial of single, ascending doses of tocilizumab 
in 18 caucasian children with sJIA in the UK 
and France [42]. All patients had evidence of 
active advanced sJIA based on a mean joint 
count of 21 swollen joints despite treatment 
with >0.2 mg/kg/day of prednisolone and 
methotrexate (≤20 mg/m2/week) in 12 patients. 
Patients received a single dose of 2, 4, or 8 mg/kg 
of tocilizumab by intravenous (i.v.) infusion. 
Treatment responses were rapid and continued 
even after serum tocilizumab levels became 
undetectable. Clinical improvement in these 
children was observed for up to 8 weeks, with 
11/18 patients achieving ACR pediatric 30 and 
8/18 patients ACR pediatric 50 or better. There 
were no observable differences with age and no 
evidence of dose-limiting toxicity. One of the 
major shortcomings of this trial is the fact that 
no adapted ACR score specific for sJIA was used 
and the authors did not comment specifically 
on the impact of tocilizumab on the systemic 
features of the disease.
These two trials eventually paved the way 
for a phase 3 randomized double-blind placebo-
controlled trial with tocilizumab in patients 
with active sJIA (the TENDER trial) [46]. The 
first part of this 5-year ongoing multinational 
study examined the safety and efficacy of 
tocilizumab administered i.v. for 12 weeks in 
112 children with active sJIA. The primary 
endpoint in this portion of the study was the 
proportion of subjects achieving at least an ACR 
pediatric 30 response plus absence of fever at 
week 12. 
Children aged 2-17 (average age 9.5) with 
an average disease duration of 5 years were 
randomized to receive placebo or tocilizumab 
at two different doses based on body weight. 
The doses used in this study were based on 
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pharmacokinetic modeling in children in the two 
earlier studies, and differed from the typical adult 
rheumatoid arthritis dose. Tocilizumab was given 
at 12 mg/kg for children with a body weight <30 kg 
or 8 mg/kg for children with a body weight ≥30 kg 
i.v. every 2 weeks. Patients were randomly 
assigned 2:1 to receive tocilizumab or placebo 
i.v. every 2 weeks for 12 weeks in a double-blind 
manner. Prior to enrollment, study participants 
had to have had active sJIA for at least 6 months 
and be unable to tolerate or not have responded 
adequately to previous treatments. In addition, 
patients had to have either five or more active 
joints or two or more active joints plus fever 
higher than 38°C for 5 or more days during the 
14-day screening period.
Patients were allowed to continue on stable 
doses of methotrexate, nonsteroidal anti-
inflammatories, or corticosteroids at a maximum 
dose of 0.5 mg/kg/day. In a significant fraction 
of the study patients prior anti-TNF and anti-IL-1 
therapy had failed. The mean age of the patients 
was 9 years, the average disease duration was 
5 years, and the average joint count at baseline 
was 20. However, only a little more than half of 
the patients (65/112 or 58%) had fevers and only 
40/112 (36%) had rashes [46]. 
Efficacy
At 12 weeks, 85% of participants receiving 
tocilizumab achieved the primary endpoint 
(≥30% improvement in ACR pediatric 30 
and absence of fever) compared with 24% of 
children receiving placebo. As a secondary 
endpoint 71% and 37% of the children in the 
tocilizumab group achieved ACR pediatric 70 
and 90 responses by week 12, compared to 
only 8% and 5% respectively of children who 
received placebo. 
In the second part of the trial, which 
examined long-term safety and efficacy, 48% 
of the patients had no actively swollen joints, 
80% achieved an ACR pediatric 70 response, 
and 59% achieved an ACR pediatric 90 response 
at week 52 of the open-label extension [47]. 
In addition, the mean oral corticosteroid 
dose decreased from 0.3 to 0.06 mg/kg, with 
discontinuation in more than half of the 
patients. Significant differences were observed 
between tocilizumab and placebo for all levels 
of response. Tocilizumab-treated patients were 
31.5-times (P<0.0001) more likely to achieve the 
primary outcome. Treatment outcomes at week 
52 were independent of prior methotrexate use 
and were similar in patients who had received 
biologic treatment prior to baseline compared 
to those with no prior biologic treatment. 
However, a higher proportion of patients who 
had not received prior biologic treatment 
achieved an ACR pediatric 90 response. This 
outcome was maintained after 2 years, when 
88% of the remaining 65 patients maintained an 
adapted ACR pediatric 70 and 46% an adapted 
ACR pediatric 90 response. Fifty-five percent 
of the patients no longer had actively swollen 
joints and about a third of the patients were 
considered to be in remission [47]. 
Safety
The most frequent side effects in the study 
were upper respiratory infections, headache, 
nasopharyngitis, and diarrhea. The most 
commonly reported infections were pneumonia, 
gastroenteritis, chickenpox, and ear infections; 
these were more frequently seen in tocilizumab-
treated patients. During the double-blind phase, 
the frequency of adverse events was similar in 
the two groups, with four serious adverse events 
in tocilizumab-treated patients. After 2 years, 
there had been 47 serious adverse events in 
35 patients, including 22 serious infections, 
leading to a death from sepsis in one patient [47]. 
Of note, since tocilizumab blocks the production 
of CRP as an acute-phase reactant, monitoring CRP 
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as marker for infection (or disease activity) may 
not be useful. Despite the absence of evidence of 
anti-tocilizumab  antibodies at baseline, infusion 
reactions were reported in 16% of patients 
in the tocilizumab group and 5% of patients 
in the placebo group, including two separate 
anaphylactic reactions in one tocilizumab-treated 
patient, who eventually was withdrawn from the 
study. Two patients developed anti-tocilizumab 
antibodies during treatment and were withdrawn 
due to adverse events. 
Three MAS episodes were reported, one 
considered by the investigator as possibly 
related to tocilizumab. In the other two 
patients withdrawal of tocilizumab and 
incomplete dosing might have contributed to 
MAS development. All patients recovered with 
standard treatment. 
Data from the 1-year analysis demonstrated 
grade 3 neutropenia (0.5-1.0×109/L) occurring in 
17 patients and grade 4 neutropenia (<0.5×109/L) 
in 2. All episodes resolved without sequelae and 
were not associated with serious infection.
Liver  enzyme e levat ions  (a lanine 
transaminase [ALT]) to grade 2 or worse (≥2.5-
times upper limit of normal [ULN]) occurred 
in 21 patients, and at least one value of total 
cholesterol and low density lipoprotein (LDL) 
cholesterol above the ULN was recorded in 31% 
and 14% of patients, respectively, compared 
with only one patient in the placebo group. 
Opportunistic infections and tuberculosis 
were not reported. A total of three deaths 
occurred during the long-term observation 
period of the trial: one in a 17-year-old boy 
from tension pneumothorax at week 50 who 
had a been well controlled on the study drug 
(ACR pediatric 90 response), one in a 4-year-old 
boy from suspected streptococcal sepsis possibly 
related to tocilizumab, and one in a 10-year-old 
boy involved in road traffic accident unrelated 
to tocilizumab. In addition to these three deaths, 
three additional deaths occurred in children 
who had completed the study and were no 
longer receiving tocilizumab. The first was in a 
13-year-old boy with a 2-year history of sJIA who 
died 6 months after the last dose of tocilizumab. 
Immediately before death he developed severe 
pulmonary hypertension and neurological 
issues. The exact cause of death was listed as 
unknown and the investigator assessed the death 
as related to a complication of the sJIA and as 
unrelated to tocilizumab. The second patient was 
almost 18 years old with a nearly 13-year history 
of sJIA at the time of death. She had very severe 
treatment-resistant sJIA and had been treated 
with three DMARDS and four biologics prior to 
enrollment in the study. She was hospitalized 
for cardiac failure and was found to have 
pulmonary veno-occlusive disease, pulmonary 
hypertension, and congestive heart failure. She 
died acutely 54 weeks after her last tocilizumab 
dose from an atrioventricular block secondary 
to hyperkalemia. The investigator assessed the 
pulmonary veno-occlusive disease as unrelated 
to tocilizumab. The third and final patient was 
almost 19 years old at the time of death and had 
had sJIA for slightly over 7 years. He initially 
had an excellent response to tocilizumab (ACR 
pediatric 90) but was withdrawn from treatment 
due to a flare with recurrence of fever and 
arthritis. Over a year later, he died suddenly 
and the primary cause of death was reported as 
cardiac arrest. The investigator considered this 
event as unrelated to the study medication. 
DISCUSSION
Where does Tocilizumab Fit in the Treatment 
of sJIA?
The approval of tocilizumab as the first biologic 
for the treatment of sJIA has enriched our 
treatment armamentarium for this historically 
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challenging disease. Similar to findings 
of previous trials with anti-TNF agents in 
polyarticular JIA, clinical outcomes with 
tocilizumab have demonstrated rapid onset and 
dramatic clinical improvements that have been 
sustained during the long-term observation 
periods. In addition, unlike canakinumab, 
tocilizumab may decrease the occurrence of MAS, 
which significantly influences the mortality 
risk in sJIA patients [40,46,47]. However, while 
the safety profile of the drug appears to be 
acceptable overall, the occurrence of five deaths 
(a sixth death was unrelated) in patients exposed 
to tocilizumab in the TENDER trial should 
heighten our awareness with regard to future 
safety data. Tocilizumab should be avoided in 
children with active acute or chronic infections, 
a known history of elevated liver or lipid levels, 
and neutropenia. Special caution should be used 
in children with a history of serious infusion 
reactions to other biologic agents.
While the results of the TENDER trial are very 
encouraging, the study population can hardly be 
described as a “systemic” population since only 
a little more than half of the patients (65/112, 
or 58%) had fevers and only 40/112 (36%) had 
rashes at baseline. In addition, the average 
disease duration was 5 years and the average 
joint count was 19 [46].
Based on a growing body of literature about 
the treatment of sJIA, it becomes increasingly 
clear that sJIA requires a more refined, disease-
stage-specific treatment strategy. Unfortunately, 
clinical trials in sJIA suffer from the fact that 
some patients with sJIA have a monocyclic 
disease course with spontaneous remission and 
frequently exclude patients in the early phase 
of the disease. In addition, patients in this 
early phase often have not yet been seen by the 
pediatric rheumatologist during the work-up 
for infection or malignancy. For the clinician, 
however, this group of patients is often the most 
challenging in terms of diagnosis, treatment, 
and risk of MAS.
Based on the summary of the clinical 
evidence from the various studies above, it 
appears that sJIA follows a fairly distinct cytokine 
pattern that correlates well with the in-vitro 
immunologic studies and the clinical response 
to the individual anticytokine treatments.
Therefore, the author would like to propose 
that sJIA is one disease entity with three fairly 
distinct but overlapping phases along the course 
of disease progression, recognizing that not all 
patients may go through all of these phases (Fig. 1). 
This differentiation is based on evidence from 
the published literature including treatment 
responses to various biologics as reviewed above 
and my personal clinical experience. Patients 
may regress to prior phases due to intermittent 
infections or recurrent disease flares. 
Phase 1 
The active systemic phase is characterized by 




Phase I Phase III
Phase II




Fig. 1. Course of systemic juvenile idiopathic arthritis 
(sJIA). Although part of a continuous spectrum and 
variable between patients, sJIA seems to follow a 
certain cytokine predominance that defines the various 
disease stages. 
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including fevers, rashes, hepatosplenomegaly, 
laboratory  ev idence  of  macrophage  
activation with elevated acute phase reactants 
(CRP, fibrinogen, thrombocytosis, anemia of 
chronic inflammation, elevated d-dimers, etc.), 
and disseminated coagulation. Initially fevers 
and rashes may not yet follow a classic quotidian 
or bi-quotidian pattern. In the past this disease 
was often referred to as Wissler syndrome, since 
patients often only had systemic symptoms 
including arthralgias but mostly no evidence of 
true arthritis [48]. This phase may precede the 
development of arthritis by weeks or even, in 
rare cases, years [9]. 
Clinically this phase most closely resembles 
an autoinflammatory syndrome, and anti-IL-1 
therapy appears to be the most effective 
treatment. Preliminary evidence seems to 
suggest that anti-IL-1 therapy in this phase 
might even prevent further disease progression 
[32]. In the personal opinion of the author, the 
role of anti-IL-6 therapy in this phase remains 
unclear, while treatment with anti-TNF agents 
appears to have little or no effect.
Phase 2 
In this overlap phase, arthritis is becoming 
increasingly prevalent, while systemic 
symptoms are still present but tend to be less 
prominent and regular than in phase 1. The 
literature quotes a progression to aggressive, 
erosive polyarticular arthritis in up to 80% of 
sJIA patients [2,3]. In this phase treatment with 
anti-IL-1 therapy appears to be less effective 
than in phase 1. Studies with rilonacept and 
canakinumab suggest a beneficial response in 
50%-60% of the patients (see above). At the 
same time treatment with anti-TNF agents 
remains suboptimal. In this phase, treatment 
with anti-IL-6 agents such as tocilizumab 
appears to be the best treatment strategy.
Phase 3
As patients progress further in their disease 
course, arthritis is becoming the predominant 
symptom, while systemic symptoms are less 
prevalent or absent. In this phase treatment with 
tocilizumab appears still to be very effective. 
However, anti-TNF treatment may regain some 
efficacy. Evidence about a treatment response 
to anti-TNF therapy in this phase can be found 
in the early etanercept and adalimumab trials 
where patients with sJIA were allowed to enroll 
as long as they had no active systemic symptoms 
[49-51]. Interestingly, some of the sJIA patients 
in the etanercept trial experienced systemic flare 
during the placebo phase in the double-blind 
randomized portion and could not be recaptured 
with etanercept once they were allowed to 
restart the active drug (unpublished personal 
observation). Treatment with anti-IL-1 therapy 
in this phase is minimally effective, as reported 
in the initial trial of anakinra in 80 children 
with a polyarticular course of JIA and similar to 
the outcomes seen in rheumatoid arthritis [37].
sJIA is a prime example of a rare childhood 
disease in which innovative approaches in basic 
science and trial and error in clinical trials with 
various modern biologic agents have taught us 
valuable lessons about the pathophysiology. 
It is apparent that sJIA requires disease-stage-
specific treatment that will ultimately lead to 
better outcomes and a decrease in mortality.
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